Diligence memo · auto-generated · as of July 3, 2026
Acanna Therapeutics, Inc.
Acanna Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Acanna Therapeutics, Inc. operates in Pharma, based in NAPLES.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Acanna Therapeutics, Inc. has raised $1.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2022-05-05.
Most recent recorded round closed around 2022-05-05.
Valuation (modeled)modeled
Provath models Acanna Therapeutics, Inc. at approximately $16M (range $560K–$104M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 6.74× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.2 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 36% of Pharma peers (310 compared).
Modeled value ranks above 41% of those peers.
Closest niche peers: Neural Therapeutics Inc., Insignis Therapeutics Inc., Atacama Therapeutics, Inc., Pharma Acuity, Inc., Arena Therapeutics OpCo, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.